Abstract
Background:
The following review is a compilation of the recent advances and knowledge on the behaviour of the most frequently used compounds to treat inflammatory bowel disease in an organism.
Results:
It considers clinical aspects of each entity and the pharmacokinetic/pharmacodynamic relationship supported by the use of plasma monitoring, tissue concentrations, and certain aspects derived from pharmacogenetics.
MeSH terms
-
Animals
-
Anti-Inflammatory Agents / adverse effects
-
Anti-Inflammatory Agents / pharmacokinetics*
-
Anti-Inflammatory Agents / therapeutic use*
-
Colitis, Ulcerative / diagnosis
-
Colitis, Ulcerative / drug therapy*
-
Colitis, Ulcerative / immunology
-
Crohn Disease / diagnosis
-
Crohn Disease / drug therapy*
-
Crohn Disease / immunology
-
Drug Monitoring
-
Gastrointestinal Agents / adverse effects
-
Gastrointestinal Agents / pharmacokinetics*
-
Gastrointestinal Agents / therapeutic use*
-
Humans
-
Pharmacogenetics
-
Remission Induction
-
Treatment Outcome
Substances
-
Anti-Inflammatory Agents
-
Gastrointestinal Agents